in vivo in PGD after LTx. Necroptosis is a programmed type of necrosis that allows a cell to commit suicide in critical circumstances, such as viral infection, or in disease (e.g., Crohn's disease, pancreatitis, and myocardial infarction) (11) . Necroptosis is initiated by the interaction of TNF with its receptor, which leads to the activation of receptor interacting serine/threonine kinase 1 (RIPK1), which in turn recruits RIPK3 to form the necrosome. The necrosome or ripoptosome recruits MLKL, which provokes cell membrane and organelle permeabilization upon oligomerization and insertion into biological lipid layers. A major difference between apoptosis and necroptosis is that apoptotic cells are rapidly cleared and thus pose only a limited risk for promoting inflammation, whereas necroptosis potentially perpetuates inflammation, in particular via the release of damage-associated molecular patterns (DAMPs) into the extracellular space. Necroptosis is often referred to as pathological cell death, whereas apoptosis appears to be a controlled and silent cell death that is involved in various processes, including development (12) .
The discovery of the contribution of necroptosis to multiplehit-induced PGD is clinically rather important because 1) available data from this model and human PGD samples have highlighted necroptosis as a conserved mechanism in PGD (5, 13), and 2) although inhibitors of necroptosis are currently being revisited and refined in preclinical models, some of them are indeed available for use in clinical trials and could be a valuable addition to current immunosuppressive regimens in LTx (14, 15) . Wang and colleagues determined that the RIPK1 inhibitor Nec1 successfully prevented the onset of necroptosis in their multiple-hit mouse model of PGD. This suggests that preclinical investigations to determine whether and the extent to which necroptosis inhibitors prevent the functional deterioration of early graft function are now needed. Such investigations could include assessments of functional readouts (e.g., the Pa O 2 /FI O 2 ratio and the wet/dry ratio) and longterm outcomes (e.g., survival) after mouse LTx.
The contributions of neutrophil-derived secretory proteins (8), such as proteases, have recently been demonstrated in PGD after LTx. DAMPs are potent neutrophil chemoattractants. Another interesting finding is that preexisting autoantibodies against collagen V (ColV) are likely to target the lung epithelium in PGD (16) . How does necroptosis affect these known mechanisms of PGD, or is affected by them? Necroptosis potentially contributes to DAMPinduced inflammation, in particular via the recruitment of additional neutrophils. It is also possible that epithelial cell death by necroptosis favors the exposure of ColV and therefore aggravates epithelial injury in PGD via the autoantibody-mediated destruction of epithelial cells. Although Wang and colleagues present evidence that epithelial cells undergo necroptosis, it is not clear whether necroptosis is restricted to this cell type. In a number of pathological contexts, neutrophils have been reported to undergo necroptosis and in turn release neutrophil extracellular traps (17) , which are known to promote PGD after LTx (7). One potential way to address compartmental restriction of necroptosis would be to use Ripk1-floxed mice crossed to diverse Cre drivers and determine whether necroptosis plays a more important role in structural/resident versus recruited immune cells. This would theoretically inform treatment: should the recipient be treated preor postoperatively, or is it possible to precondition the graft? Another important issue to address is the timing of the onset of necroptosis: is it initiated after reperfusion or during graft preservation? In the latter case, it would be sensible to supplement the ex vivo conditioning medium with necroptosis inhibitors before implanting the graft.
In conclusion, PGD remains a major limitation to the survival and quality of life of patients who have undergone LTx, in particular because there is no consensus on the potential treatment options to prevent PGD. The current study by Wang and colleagues highlights a new mechanism that may aid in the development of novel therapeutic targets for PGD. The authors should be applauded for establishing and interrogating a novel and complex multiple-hit model of PGD. Their study constitutes a solid foundation for future investigations to assess the effects of necroptosis inhibitors on long-term outcomes of PGD in preclinical and potentially clinical studies. n
